FLT3 (fms-like tyrosine kinase 3), also known as CD135, FLK2 (fetal liver kinase 2), and STK1 (stem cell tyrosine kinase 1), is a single pass type I transmembrane protein belonging to the receptor tyrosine kinase (RTK) family and the CSF-1/PDGF receptor subfamily. FLT3 contains one immunoglobulin (Ig)-like C2-type domains in the extracellular domain (ECD) and 1 tyrosine kinase domain in the cytoplasmic region. FLT3 is detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells. It is highly expressed in T-cell leukemia.  FLT3 acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. FLT3 is present in an inactive conformation in the absence of bound ligand and FLT3LG binding leads to homodimerization and activation by autophosphorylation. FLT3 promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effectors including mTOR and RAS, leading to phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations in FLT3 that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis, resulting in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

FLT3 (fms-like tyrosine kinase 3), also known as CD135, FLK2 (fetal liver kinase 2), and STK1 (stem cell tyrosine kinase 1), is a single pass type I transmembrane protein belonging to the receptor tyrosine kinase (RTK) family and the CSF-1/PDGF receptor subfamily. FLT3 contains one immunoglobulin (Ig)-like C2-type domains in the extracellular domain (ECD) and 1 tyrosine kinase domain in the cytoplasmic region. FLT3 is detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells. It is highly expressed in T-cell leukemia.  FLT3 acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. FLT3 is present in an inactive conformation in the absence of bound ligand and FLT3LG binding leads to homodimerization and activation by autophosphorylation. FLT3 promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effectors including mTOR and RAS, leading to phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations in FLT3 that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis, resulting in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

 

Product Details

 

Gene Symbol: FLT3; FLK2; STK1; CD135; FLK-2

 

NCBI Gene ID: 2322

 

Uniprot Entry: P36888

 

Construct Details: Full length human FLT3 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without a selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles. Multiple choices of a stable antibiotic selection marker are available.

 

Vector Type: pLTC or pLTC-IRES-Marker (lentiviral expression vector containing a heterologous CMV promoter +/- a selection marker, see the vector map above)

 

Formulation: Supplied with 10 μg of endotoxin-free plasmid DNA at 200 ng/μl in sterile TE buffer (pH8.0)

 

Gene Insert Size: 2982 (bp)

 

Gene Insert Sequence:  

ATGCCGGCGTTGGCGCGCGACGGCGGCCAGCTGCCGCTGCTCGTTGTTTTTTCTGCAATGATATTTGGGA

CTATTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTTTAATCAATCATAAGAACAATGATTCATCAGT

GGGGAAGTCATCATCATATCCCATGGTATCAGAATCCCCGGAAGACCTCGGGTGTGCGTTGAGACCCCAG

AGCTCAGGGACAGTGTACGAAGCTGCCGCTGTGGAAGTGGATGTATCTGCTTCCATCACACTGCAAGTGC

TGGTCGACGCCCCAGGGAACATTTCCTGTCTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACA

TTTTGATTTACAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCCAAGCTGGAGAA

TACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACAATATTGTTTACAGTGAGTATAAGAAATACCC

TGCTTTACACATTAAGAAGACCTTACTTTAGAAAAATGGAAAACCAGGACGCCCTGGTCTGCATATCTGA

GAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGATTCACAGGGGGAAAGCTGTAAAGAAGAAAGT

CCAGCTGTTGTTAAAAAGGAGGAAAAAGTGCTTCATGAATTATTTGGGACGGACATAAGGTGCTGTGCCA

GAAATGAACTGGGCAGGGAATGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCTCAGACCACATT

GCCACAATTATTTCTTAAAGTAGGGGAACCCTTATGGATAAGGTGCAAAGCTGTTCATGTGAACCATGGA

TTCGGGCTCACCTGGGAATTAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATGAGTACCTATT

CAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGTGGCAAGAAACGACACCGGATA

CTACACTTGTTCCTCTTCAAAGCATCCCAGTCAATCAGCTTTGGTTACCATCGTAGAAAAGGGATTTATA

AATGCTACCAATTCAAGTGAAGATTATGAAATTGACCAATATGAAGAGTTTTGTTTTTCTGTCAGGTTTA

AAGCCTACCCACAAATCAGATGTACGTGGACCTTCTCTCGAAAATCATTTCCTTGTGAGCAAAAGGGTCT

TGATAACGGATACAGCATATCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGCA

GAAAATGATGATGCCCAATTTACCAAAATGTTCACGCTGAATATAAGAAGGAAACCTCAAGTGCTCGCAG

AAGCATCGGCAAGTCAGGCGTCCTGTTTCTCGGATGGATACCCATTACCATCTTGGACCTGGAAGAAGTG

TTCAGACAAGTCTCCCAACTGCACAGAAGAGATCACAGAAGGAGTCTGGAATAGAAAGGCTAACAGAAAA

GTGTTTGGACAGTGGGTGTCGAGCAGTACTCTAAACATGAGTGAAGCCATAAAAGGGTTCCTGGTCAAGT

GCTGTGCATACAATTCCCTTGGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTTT

CATCCAAGACAACATCTCATTCTATGCAACAATTGGTGTTTGTCTCCTCTTCATTGTCGTTTTAACCCTG

CTAATTTGTCACAAGTACAAAAAGCAATTTAGGTATGAAAGCCAGCTACAGATGGTACAGGTGACCGGCT

CCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAG

AGAAAATTTAGAGTTTGGGAAGGTACTAGGATCAGGTGCTTTTGGAAAAGTGATGAACGCAACAGCTTAT

GGAATTAGCAAAACAGGAGTCTCAATCCAGGTTGCCGTCAAAATGCTGAAAGAAAAAGCAGACAGCTCTG

AAAGAGAGGCACTCATGTCAGAACTCAAGATGATGACCCAGCTGGGAAGCCACGAGAATATTGTGAACCT

GCTGGGGGCGTGCACACTGTCAGGACCAATTTACTTGATTTTTGAATACTGTTGCTATGGTGATCTTCTC

AACTATCTAAGAAGTAAAAGAGAAAAATTTCACAGGACTTGGACAGAGATTTTCAAGGAACACAATTTCA

GTTTTTACCCCACTTTCCAATCACATCCAAATTCCAGCATGCCTGGTTCAAGAGAAGTTCAGATACACCC

GGACTCGGATCAAATCTCAGGGCTTCATGGGAATTCATTTCACTCTGAAGATGAAATTGAATATGAAAAC

CAAAAAAGGCTGGAAGAAGAGGAGGACTTGAATGTGCTTACATTTGAAGATCTTCTTTGCTTTGCATATC

AAGTTGCCAAAGGAATGGAATTTCTGGAATTTAAGTCGTGTGTTCACAGAGACCTGGCCGCCAGGAACGT

GCTTGTCACCCACGGGAAAGTGGTGAAGATATGTGACTTTGGATTGGCTCGAGATATCATGAGTGATTCC

AACTATGTTGTCAGGGGCAATGCCCGTCTGCCTGTAAAATGGATGGCCCCCGAAAGCCTGTTTGAAGGCA

TCTACACCATTAAGAGTGATGTCTGGTCATATGGAATATTACTGTGGGAAATCTTCTCACTTGGTGTGAA

TCCTTACCCTGGCATTCCGGTTGATGCTAACTTCTACAAACTGATTCAAAATGGATTTAAAATGGATCAG

CCATTTTATGCTACAGAAGAAATATACATTATAATGCAATCCTGCTGGGCTTTTGACTCAAGGAAACGGC

CATCCTTCCCTAATTTGACTTCGTTTTTAGGATGTCAGCTGGCAGATGCAGAAGAAGCGATGTATCAGAA

TGTGGATGGCCGTGTTTCGGAATGTCCTCACACCTACCAAAACAGGCGACCTTTCAGCAGAGAGATGGAT

TTGGGGCTACTCTCTCCGCAGGCTCAGGTCGAAGATTCGTAG

 

 

Primers: Gene insert coding sequence can be confirmed by following primers:

(a) forward (or 5'-end) primer: 5’-CAAATGGGCGGTAGGCGTG-3’;

(b) reverse (or 3'-end) primer: 5’-CCAGGTTTCCGGGCCCTCAC-3’

 

 

Note: The sequence may vary due to the naturally occurring variants or mutations, such as single nucleotide polymorphism, or the artifact during PCR amplification.  High fidelity PCR systems should always be used. 

 

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 6 months. 

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Blood 82:1110-1119(1993)

2. Genomics 9:380-385(1991) 

3. Leukemia 10:238-248(1996)

4. Cancer Res. 65:9643-9650(2005)

5. J. Immunol. 180:7358-7367(2008)

 

 

Additional supporting documents, including product data sheet (PDS), COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.